Severe asthma, particularly the subset of patients dependent on daily oral corticosteroids, poses a considerable therapeutic challenge. Long-term OCS use, while effective in controlling inflammation and preventing exacerbations, comes at a steep cost. Patients frequently suffer from serious side effects such as osteoporosis, diabetes, and cardiovascular complications, in addition to a decreased overall quality of life. The quest for therapies that diminish the necessity for systemic steroids yet maintain disease control has been a critical focus of contemporary asthma research.

Tezepelumab, an anti-alarmin monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), intervenes early in the inflammatory cascade driving asthma pathogenesis. By inhibiting TSLP, tezepelumab modulates various downstream pathways implicated in type 2 and non-type 2 airway inflammation. This broad mechanism of action positions tezepelumab as a potentially effective treatment across a wide spectrum of severe asthma phenotypes, including those traditionally refractory to existing biologic agents.

The SUNRISE trial, a multicenter, double-blind, placebo-controlled study, meticulously evaluated the efficacy and safety profile of tezepelumab in adults reliant on daily oral corticosteroids despite high-dose inhaled therapies. The rigor of the double-blind design ensured unbiased assessment of outcomes. Patients receiving tezepelumab were nearly three times more likely than their placebo counterparts to achieve substantial reductions in their daily oral corticosteroid dose, all while retaining stable asthma control—a testament to the drug’s robust therapeutic potential.

Over the 28-week treatment duration, the trial revealed that 69% of patients administered tezepelumab succeeded in reducing their oral corticosteroid intake by at least 50%. In stark contrast, only 44% of placebo-treated patients reached a similar milestone. Even more striking was the complete cessation of oral corticosteroids by 35% of those treated with tezepelumab, versus just 21% in the placebo group. These figures underscore tezepelumab’s capacity to mitigate steroid-associated burden profoundly.

Maintaining asthma control during corticosteroid tapering is notoriously difficult; however, tezepelumab demonstrated that significant reductions in systemic steroid use need not precipitate worsened symptoms or exacerbations. This dual achievement—decreasing steroid dependence while preserving disease stability—addresses a critical unmet need in severe asthma management. It opens a promising therapeutic avenue, offering patients a chance for improved health outcomes with fewer adverse effects.

Importantly, the mechanism through which tezepelumab operates offers unique advantages over other biologics currently available. By targeting TSLP, an epithelial-cell derived cytokine instrumental in initiating multiple inflammatory pathways, tezepelumab disrupts upstream signaling rather than focusing on a single downstream mediator. This comprehensive inhibition may be why its benefits extend to patients whose asthma is resistant to other targeted treatments, including those not characterized by classic type 2 inflammation biomarkers.

The reduction in oral corticosteroid burden achieved with tezepelumab is expected to translate into tangible clinical benefits beyond asthma control. Chronic corticosteroid exposure is a well-documented risk factor for systemic complications, including metabolic syndrome, adrenal suppression, and heightened susceptibility to infection. Thus, treatments facilitating steroid sparing not only improve respiratory outcomes but also reduce long-term morbidity associated with corticosteroid toxicity.

In addition to dose reduction and steroid discontinuation proportions, tezepelumab treatment was associated with improved key clinical outcomes such as decreased exacerbation frequency, enhanced lung function, and better patient-reported quality of life indices. These multifactorial benefits reinforce the comprehensive therapeutic value of tezepelumab in tackling the multidimensional burdens faced by patients with severe asthma.

Dr. Michael Wechsler, the lead investigator and director of the Cohen Family Asthma Institute at National Jewish Health, emphasized the profound implications of these results. He highlighted that the ability to significantly taper corticosteroid use without sacrificing asthma stability could revolutionize patient care, markedly reducing the incidence of steroids’ debilitating side effects. This landmark achievement may redefine the therapeutic landscape for corticosteroid-dependent asthma populations worldwide.

The SUNRISE trial’s rigor and its promising findings herald a new era in biologic treatments for severe asthma. As tezepelumab gains wider clinical application, its role in personalized medicine becomes increasingly apparent. By tailoring treatment strategies grounded in molecular and clinical phenotyping, clinicians can optimize outcomes, minimizing treatment risks while maximizing efficacy.

In conclusion, the Phase 3 SUNRISE study establishes tezepelumab as a powerful and innovative therapeutic option that significantly reduces oral corticosteroid dependence in adults with severe asthma. Its unique mode of action, combined with demonstrated effectiveness and an encouraging safety profile, positions tezepelumab to set a new standard in the management of corticosteroid-dependent severe asthma. The findings offer hope and a tangible path forward for thousands of patients burdened by the twin challenges of severe respiratory disease and steroid-associated morbidity.

Subject of Research: Severe asthma treatment, oral corticosteroid reduction, biologic therapy

Article Title: Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial

News Publication Date: 18-May-2026

Web References:

• https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213260026000767
• http://dx.doi.org/10.1016/S2213-2600(26)00076-7

Keywords: Severe asthma, tezepelumab, oral corticosteroids, corticosteroid-sparing therapy, TSLP inhibition, biologics, Phase 3 clinical trial, airway inflammation

In the PASSAGE study, the research team scrutinized the multifaceted nature of severe asthma, focusing on pediatric and adult populations across various demographics. This approach is particularly crucial given that asthma can manifest differently depending on genetic, environmental, and social factors. The results of the initial analysis indicated that Tezepelumab not only reduced the frequency of asthma exacerbations but also improved overall pulmonary function. Such findings offer a glimmer of hope for those who have struggled to find effective management strategies amidst the myriad of options available in conventional asthma therapies.

Severe asthma remains a worldwide burden, with an estimated 5-10% of asthmatic individuals classified as having severe persistent asthma. This subset often relies on high-dose inhaled corticosteroids and oral corticosteroids, treatments that bring substantial side effects and limited efficacy. The efficacy of Tezepelumab introduces a paradigm shift, where patients may potentially reduce their reliance on steroids while achieving better control over their asthma. The implications of this are enormous—potentially decreasing hospital visits, improving quality of life, and lowering healthcare costs associated with uncontrolled asthma.

One notable strength of the PASSAGE study lies in its robust and diverse population sample. The representation of different ethnicities, age groups, and geographical locations offers a comprehensive insight into how Tezepelumab performs across varied patient profiles. Such heterogeneity enriches the research findings, affirming that the treatment could be universally applicable. Although the preliminary results are compelling, ongoing research will be vital to ascertain long-term safety and efficacy outcomes.

The need for targeted therapy in asthma management cannot be overstated. Conventional treatments often fail to address the underlying biological mechanisms of the disease, leading to persistent symptoms. Tezepelumab operates at the very beginning of the inflammatory chain, which may render it advantageous over existing treatments. As the scientific community continues to explore biologics for asthma, Tezepelumab sets a pivotal precedent by targeting disease initiation rather than just the manifestations.

Moreover, the safety profile of the drug is critical to its acceptance among healthcare providers and patients alike. Early data suggest that Tezepelumab is generally well-tolerated, with fewer adverse effects than those commonly associated with corticosteroids. However, vigilance in monitoring for rare but serious side effects remains paramount, especially given the complexities of individual patient health profiles. Safety data will be monitored closely in ongoing studies to support the claims surrounding its tolerability.

It is also important to consider the burden of asthma on healthcare systems. The economic implications of severe asthma are staggering, with direct costs including hospitalization, medications, and outpatient care, as well as indirect costs resulting from lost productivity. With the introduction of Tezepelumab, there is the potential for significant advancements in patient management that could alleviate these financial strains on society.

As researchers gather more data from various clinical trials, understanding the pharmacodynamics of Tezepelumab will be essential. The drug’s mechanism—blocking TSLP—could also extend to other allergic conditions, suggesting that its future applications may transcend the realm of asthma treatment alone. There is a growing interest in the broader immunological implications, especially in diseases characterized by Th2 inflammation, where cytokine modulation could pave the way for new therapeutic interventions.

The landscape of asthma treatment is changing, and biologic therapies such as Tezepelumab serve as a beacon for hope amid traditional steroid-based management. As the research community works tirelessly to refine and expand these findings, patient advocacy groups are also encouraged to pay attention to emerging data, utilizing it to inform and empower their communities. The results and subsequent corrections from the PASSAGE study provide comprehensive insights into the potential for steroid-sparing therapies within specialized care.

In conclusion, the advancements brought forth by Tezepelumab may very well signify a crucial turning point in the management of severe asthma. With continued research support, collaboration between clinicians and researchers, and the incorporation of patient perspectives, the ongoing exploration of Tezepelumab will keep moving forward. The journey from the lab to clinical practice remains fraught with challenges, but with promising data at hand, we are one step closer to achieving better control and improved quality of life for asthma patients worldwide.

Subject of Research: Tezepelumab and its effectiveness and safety for severe asthma patients.

Article Title: Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study.

Article References:

Lugogo, N.L., Akuthota, P., Sumino, K. et al. Correction to: Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study. Adv Ther 42, 4724–4725 (2025). https://doi.org/10.1007/s12325-025-03316-2

Image Credits: AI Generated

DOI: 10.1007/s12325-025-03316-2

Keywords: Tezepelumab, asthma, cytokines, TSLP, severe asthma, PASSAGE study, biologics, safety, efficacy, chronic inflammation, treatment guidelines.